Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Veradigm Inc.
  6. Summary
    MDRX   US01988P1084

VERADIGM INC.

(MDRX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
17.00 USD   -1.73%
02/01Jopari Solutions and Veradigm Collaborate to Provide Electronic Claim & Attachment Solutions for Veradigm Payerpath™ Customers
CI
02/01Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $18.50 From $17
MT
01/31Veradigm Network EHR Data is Now Available in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) Format
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/31/2023 02/01/2023 02/02/2023 02/03/2023 02/06/2023 Date
17.91(c) 17.34(c) 17.3(c) 17.3(c) 17(c) Last
948 214 1 045 537 1 013 161 976 197 816 868 Volume
+1.82% -3.18% -0.23% 0.00% -1.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 615 M - -
Net income 2022 1,05 M - -
Net cash position 2022 376 M - -
P/E ratio 2022 -425x
Yield 2022 -
Sales 2023 656 M - -
Net income 2023 71,7 M - -
Net cash position 2023 333 M - -
P/E ratio 2023 28,6x
Yield 2023 -
Capitalization 1 857 M 1 857 M -
EV / Sales 2022 2,41x
EV / Sales 2023 2,32x
Nbr of Employees 8 000
Free-Float 38,1%
More Financials
Company
Veradigm, Inc., formerly Allscripts Healthcare Solutions, Inc., delivers healthcare information technology (IT) solutions to help healthcare organizations achieve clinical, financial and operational results. The Company's solutions helps to connect people, places and data across an Open Connected Community of Health. It offers payer and life sciences solutions, which are mainly targeted at payers, life sciences... 
Read more
More about the company
Ratings of Veradigm Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about VERADIGM INC.
02/01Jopari Solutions and Veradigm Collaborate to Provide Electronic Claim & Attachment Solu..
CI
02/01Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $..
MT
01/31Veradigm Network EHR Data is Now Available in the Observational Medical Outcomes Partne..
AQ
01/30Veradigm® Network EHR Data is Now Available in the Observational Medical Outcomes Partn..
BU
01/11Transcript : Veradigm Inc. Presents at 41st Annual J.P. Morgan Healthcare Con..
CI
01/11Veradigm Approves Share Buyback Plan of Up to $250 Million, Provides Fiscal 2023 Guidan..
MT
01/11Veradigm Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/11Tranche Update on Veradigm Inc.'s Equity Buyback Plan announced on January 24, 2022.
CI
01/11Veradigm Inc. announces an Equity Buyback for $250 million worth of its shares.
CI
01/11Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fisc..
BU
01/11Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2023
CI
01/11Veradigm Inc. s Equity Buyback announced on January 24, 2022 has expired.
CI
01/11Veradigm Inc. authorizes a Buyback Plan.
CI
01/10Veradigm Building Momentum Across All Markets
BU
01/10Veradigm Makes Investment in Behavioral Health Data Analytics Company Holmusk
MT
More news
News in other languages on VERADIGM INC.
02/01Jopari Solutions et Veradigm collaborent pour fournir des solutions de réclamations et ..
01/11Veradigm approuve un plan de rachat d'actions pouvant atteindre 250 millions de dollars..
01/11Veradigm Inc. (NasdaqGS:MDRX) annonce un rachat d'actions pour u..
01/11Veradigm Inc. fournit des prévisions de bénéfices pour l'année fiscale 2023
01/11Veradigm Inc. autorise un plan de rachat.
More news
Analyst Recommendations on VERADIGM INC.
More recommendations
ETFs positioned on VERADIGM INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Global X Telemedicine & Digital Health Dist - GBP3.41%3.16%-NC
Global X Telemedicine & Digital Health - USD3.41%0.16%-NC
Global X Telemedicine & Digital Health ETF - USD3.4%0.08%-NC
Invesco Dynamic Software ETF - USD2.85%2.09%United_States
Fidelity Digital Health ACC - USD1.93%1.99%-NC
More ETFs positioned on VERADIGM INC.
Chart VERADIGM INC.
Duration : Period :
Veradigm Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERADIGM INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 17,00 $
Average target price 22,07 $
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Richard J. Poulton Chief Executive Officer & Director
Thomas Langan President
Leah Jones Vice President-Finance & Sales Support
Joseph R. Rostock Chief Technology Officer & SVP-Product Engineering
Tejal Vakharia Chief Compliance Counsel & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
VERADIGM INC.-3.63%1 857
VEEVA SYSTEMS INC.7.86%27 101
PRO MEDICUS LIMITED21.59%4 822
EVOLENT HEALTH, INC.10.43%3 090
SECTRA AB (PUBL)7.24%2 896
OMNICELL, INC.13.70%2 473